Publication details

Rezistence na imatinib a možnosti využití vyššího dávkování léku u pacientů s chronickou myeloidní leukemií

Title in English Resistance to imatinib and the possibilities of use of the dose escalation of the drug in patients with chronic myeloid leukemia
Authors

MAYER Jiří KLAMOVÁ H. ŽÁČKOVÁ Daniela DOUBEK Michael CETKOVSKÝ Petr KREJČÍ Marta DVOŘÁKOVÁ Dana

Year of publication 2007
Type Article in Periodical
Magazine / Source Transfúze a hematologie dnes
MU Faculty or unit

Faculty of Medicine

Citation
Field Oncology and hematology
Keywords chronic myeloid leukemia; imatinib; resistance to imatinib; BCR-ABL; BCR-ABL kinase domain mutations; dasatinib; nilotinib
Description The introduction of imatinib into the treatment of chronic myeloid leukemia represents a revolutionary therapeutic approach. Together with its excellent results, the issue of imatinib resistance - the significant cause of therapeutic failure - has emerged. The authors pay attention to the relation of the mechanism of action, pharmacokinetics and pharmacodynamics to the imatinib treatment results in the scale ranging from the BCR-ABL transcript reduction to the overall survival. In addition, the most frequent mechanisms of imatinib resistance, particularly the data about the BCR-ABL kinase domain mutations are summarized and the possibilities of the management of this problem are discussed. Besides the dose escalation of imatinib the new promising agents, particularly dasatinib and nilotinib are presented and discussed.

You are running an old browser version. We recommend updating your browser to its latest version.

More info